BioSpace News Archive

Taysha Gene Therapies today announced positive longer-term clinical data from the ongoing REVEAL Phase 1/2 adolescent and adult trial and initial clinical data from the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome.

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has completed the sale of a 20% equity stake in Shanghai RAAS to Haier Group Corporation and forged a strategic alliance with Haier Group.

ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massachusetts.

Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), is pleased to announce that it has been selected to present the data from its latest Alzheimer’s study in an extended 45-minute session at the Alzheimer’s Association International Conference® 2024 (AAIC®).

CorMedix Inc. announced that the U.S. Food and Drug Administration has provided feedback to the Company’s request to discuss development plans for additional indications for DefenCath.

Erasca, Inc. today announced the initiation of the global SEACRAFT-2 Phase 3 trial evaluating the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib (MEKINIST®) in patients with NRAS-mutant (NRASm) melanoma.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as MSD outside the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE.

Gamida Cell today announced new executive leadership following a successful restructuring transaction (“Transaction”) with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) on May 24, 2024.

Reveal Genomics® to Evaluate Prospective Real-time Performance of HER2DX ® Genomic Test in the United States.

Intelligent Bio Solutions Inc. today announced that it is entering the next phase of its planned 510(k) submission to the FDA.